• LAST PRICE
    2.6000
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-0.7634%)
  • Bid / Lots
    2.6000/ 18
  • Ask / Lots
    2.6400/ 2
  • Open / Previous Close
    2.7200 / 2.6200
  • Day Range
    Low 2.4700
    High 2.7200
  • 52 Week Range
    Low 1.3910
    High 4.8800
  • Volume
    45,468
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.62
TimeVolumeMNPR
09:32 ET12902.72
09:37 ET33702.5
09:39 ET1002.5
09:42 ET1002.5799
09:44 ET64002.58
09:50 ET3002.6815
09:51 ET1502.49
09:55 ET1002.605
10:04 ET36762.6
10:06 ET25502.51
10:08 ET1002.6908
10:15 ET21002.7099
10:47 ET9052.595
11:39 ET1002.5966
01:29 ET1002.6201
01:45 ET2002.62
01:54 ET1002.62
02:09 ET8002.67
02:14 ET2002.635
02:21 ET25162.58
02:25 ET61102.59
02:30 ET31002.56
02:38 ET1002.6499
02:39 ET56022.63
02:41 ET23002.6112
02:43 ET2002.6
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMNPR
Monopar Therapeutics Inc
33.7M
-3.2x
---
United StatesELDN
Eledon Pharmaceuticals Inc
33.8M
-0.9x
---
United StatesBCEL
Atreca Inc
34.2M
-0.3x
---
United StatesAVRO
AVROBIO Inc
34.4M
-0.3x
---
United StatesBTTX
Better Therapeutics Inc
34.4M
-0.5x
---
United StatesASLN
Aslan Pharmaceuticals Ltd
34.8M
-0.9x
---
As of 2022-12-09

Company Information

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutics designed to extend life or improve the quality of life for cancer patients. The Company's pipeline consists of Validive, camsirubicin, MNPR-101, MNPR-101 RIT and MNPR-202. Its lead product candidate, Validive is under Phase IIb/III clinical trial for the prevention of chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (VOICE trial). The Company also commenced a United States-based open-label, Phase Ib clinical trial of camsirubicin for the treatment of advanced soft tissue sarcoma (ASTS). Its three preclinical programs include MNPR-101, which targets antibody for the treatment of various cancers; MNPR-101 RIT, which continues development for the treatment of cancer and severe COVID-19 in collaboration; and MNPR-202, an analog of camsirubicin designed to treat doxorubicin and camsirubicin-resistant cancers.

Contact Information

Headquarters
1000 Skokie Blvd Ste 350WILMETTE, IL, United States 60091-1146
Phone
847-388-0349
Fax
302-655-5049

Executives

Executive Independent Chairman of the Board
Christopher Starr
Chief Executive Officer, Director
Chandler Robinson
Chief Financial Officer, Treasurer, Secretary
Kim Tsuchimoto
Chief Operating Officer
Andrew Cittadine
Acting Chief Medical Officer
Patrice Rioux

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$33.7M
Revenue (TTM)
$0.00
Shares Outstanding
12.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.81
Book Value
$1.50
P/E Ratio
-3.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.